Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How about Oncolym in 1993--talk about frustrated...
OT EZ are you going to the pphm presentation in dc?
I have two accounts. I thought I had voted online on both accounts, but apparently I hadn't.
I just received written confirmation of the telephone proxy from last week and the instructions were erred. I voted against the stock incentive plan and the written confirmation indicated I voted for it. For those of you that voted via solicited telephone, look real carefully at your confirmations when they arrive.
I was called last evening as well. Voted no on all but auditors.
Maybe because Dr. Thorpe was there in the late 90's, I believe, for a short time. My Dad was a patient there at the time but I didn't get a chance to meet the Dr.
Why no mention of DTRA?
Does anyone know if REGN's vegf drug for macular degeneration conflicts with our patents in this category?
Are you folks going to do an IST? If so, when?
I asked a similar question of Amy some months ago and did not get an answer.
Poster T02-003
Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential broad-Spectrum Antiviral Therapy
Kara Corbin-Lickfett, Peregrine Pharmaceuticals
I'm surprised that a malaria trial hasn't been started. Seems like a natural with the BMGFoundation.
Is this the Duke paper?
http://www.nature.com/nm/journal/vaop/ncurrent/index.html
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
Sampa Santra, Hua-Xin Liao, Ruijin Zhang, Mark Muldoon, Sydeaka Watson, Will Fischer, James Theiler, James Szinger, Harikrishnan Balachandran, Adam Buzby, David Quinn, Robert J Parks, Chun-Yen Tsao, Angela Carville, Keith G Mansfield, George N Pavlakis, Barbara K Felber, Barton F Haynes, Bette T Korber & Norman L Letvin
Published online: 21 February 2010 | doi:10.1038/nm.2108
I'm a little skeptical. Has anyone seen the crows yet???????
At one point Pro 2000 belonged to Indevus Pharm (IDEV).
Is it possible to gain approval in India or Georgia and begin marketing there far ahead of the U.S.? I should think the India market would be huge. Wonder if we'll ever hear any more out of China?
Didn't Dr. Soares or Thorpe talk about immunity in relation to Pinchide or Lassa Fever a few years ago at the ASM?
Here is the reply to my H1N1 question.
From: ir@biocompartners.com
> To: docksinc@aol.com
> Sent: 10/28/2009
> 9:36:19 A.M. Pacific Daylight Time
> Subj: Re: H1N1
>
>
>
>
>
> While bavituximab has exhibited
> promise as an anti-viral
> agent in a number of the viruses that it has been
> tested in, bavituximab
> has not been tested against H1N1. Because
> there are a number of
> products closer to approval for use against H1N1,
> we would not expect an
> Emergency Use Authorization for bavituximab at this
> time.
>
> Thank
> you for your support of Peregrine.
>
>
>
>
>
>
>
>
>
>
>
>
> Sent: Saturday, October
> 24, 2009 10:35
> AM
> To: Investor
> Relations
> Subject:
> H1N1
>
> The following
> comment was
> submitted via the Peregrine Pharmaceuticals, Inc.
> website by Roger
> Mathias [docksinc@aol.com].
> Has Bavituximab been tested on
> H1N1 virus? Is EUA for H1N1 a possibility now that
> the Pres. has
> declared a flu
> emergency?
I asked IR over the weekend about H1N1. I'll post their reply if they reply.
http://www.reuters.com/article/marketsnews/idINN1532890720090715?rpc=33&pageNumber=1&virtualBrandChannel=0
Clock ticking on firms that tripped listing rules
Wed Jul 15, 2009 2:07pm EDT Email | Print | Share| Reprints | Single Page[-] Text [+]
* Nasdaq, NYSE to resume listing enforcement Aug. 3
* Up to 103 companies now failing to meet U.S. rules
* Pain on horizon for companies, and perhaps exchanges
By Jonathan Spicer
NEW YORK, July 15 (Reuters) - Time is running out on as many as 103 public companies now running afoul of rules for staying listed on the major U.S. stock markets.
At the end of this month, temporary reprieves granted by the New York Stock Exchange and the Nasdaq Stock Market will expire, putting renewed pressure on companies that have suffered more than most in the financial crisis and economic slump.
Last fall, the Nasdaq decided to waive its market capitalization and $1 minimum share price requirements to avoid a pending crush of delistings brought on by the severe market drop. The Big Board followed suit in the winter, the first time the centuries-old exchange made such a rule change.
The exchange operators extended those rule suspensions a few times over the last several months, but NYSE Euronext (NYX.N)(NYX.PA) and Nasdaq OMX (NDAQ.O) recently told the U.S. Securities and Exchange Commission they will again start enforcing the listing rules Aug. 3. [ID:nN14300532]
With another extension unlikely, as many as 71 Nasdaq-listed companies and 32 NYSE-listed companies that now fall below the threshholds will face delisting next month, according to the latest data from the exchanges.
The numbers are down from October, when Nasdaq said 344 companies were under the $1 share price rule, and from February, when NYSE said more than 50 listings were about to disappear from the exchange. Nasdaq has some 2,900 U.S. listings, while NYSE has 2,200.
This month, Nasdaq said in a regulatory filing it "does not expect a further extension of the suspension beyond July 31."
That is bad news for companies such as NYSE-listed Internet calling company Vonage Holdings Corp (VG.N) and newspaper publisher McClatchy Co (MNI.N), as well as Nasdaq-listed drug company Peregrine Pharmaceuticals (PPHM.O).
Is anyone having trouble getting connected?
Is this what we're waiting on?
New Strategy Proposed For Designing Antibody-based HIV Vaccine
ScienceDaily (June 16, 2009) — Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful.
--------------------------------------------------------------------------------
See also:
Health & Medicine
HIV and AIDS
Infectious Diseases
STD
Plants & Animals
Virology
Horses
Bird Flu Research
Reference
Antiviral drug
HPV vaccine
Hepatitis B
Flu vaccine
But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and colleagues.
These studies demonstrate that, contrary to widespread belief, it is not uncommon for people infected with HIV to naturally make antibodies that can neutralize a variety of HIV strains. These antibodies do not protect people from the virus because they arise years after HIV infection is established. However, if a vaccine could prime the body to make these broadly neutralizing antibodies before exposure to HIV, they could potentially prevent infection or hold the virus at bay until an army of immune cells assembles to limit viral replication.
Based on these findings, Dr. Mascola and colleagues recommend a research strategy that uses naturally occurring, broadly neutralizing anti-HIV antibodies for the ultimate design of an antibody-based HIV vaccine.
Key aspects of this strategy include:
Obtaining new broadly neutralizing antibodies to HIV to expand the pool available for scientists to study
Identifying regions on the surface of HIV that are vulnerable to broadly neutralizing antibodies and determining the atomic-level crystal structure of those regions
Understanding how broadly neutralizing antibodies to HIV evolve and persist
Clarifying the structural differences between anti-HIV antibodies that do and do not have neutralizing properties
Determining what quantity of broadly neutralizing antibodies an HIV vaccine must elicit to be effective
Learning how anti-HIV neutralizing antibodies and HIV surface proteins evolve in response to one another in people who eventually produce a powerful neutralizing antibody response to the virus
Clarifying how HIV surface proteins are presented to the immune cells that produce broadly neutralizing antibodies to HIV
Determining what immune-system conditions promote the production of broadly neutralizing anti-HIV antibodies
--------------------------------------------------------------------------------
Journal reference:
Stamatatos et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Medicine, 2009; DOI: 10.1038/nm.1949
Has anyone heard anything about the Selectine trial with Merck AG in Switzerland?
Do we know if the Gates foundation is aware of Bavi's action on Malaria? Seems like a natural thing for them to jump on.
Probably not. Went to conference website and no sign of PPHM on agenda.
Is PPHM presenting at the conference this week--jp morgan I think.......
I thought the DTRA was going to give us $5 million up front last quarter. What happened to that?
Could you elaborate on the cranial removal for Cotara. I thought it was administered via catheter. I hadn't heard about a craniotomy with Cotara; Gliadel yes.
Count me in!
Avastin may increase risk of neural bleeding and stroke in patients with glioblastoma multiforme, physicians say
By Klara Czobor
Published: September 18 2008 13:24 | Last updated: September 18 2008 13:24
This article is provided to FT.com readers by Pharmawire—a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.pharmawire.com
--------------------------------------------------------------------------------------------------------
Avastin (bevacizumab) may increase the risk of neural bleeding and stroke in a small population of patients with glioblastoma multiforme, according to several physicians interviewed by Pharmawire. The gravity of this side-effect should be carefully studied, they added.
The drug acts by targeting vascular endothelial growth factor (VEGF) and is thought to act by blocking the formation of new blood vessels (angiogenesis). The drug is approved by the FDA for the treatment of patients with non-small cell lung cancer, colorectal cancer and metastatic breast cancer. Avastin is currently undergoing Phase II clinical studies in patients with glioblastoma multiforme.
A significant side-effect of Avastin is that the drug’s administration may cause bleeding complications in the brain, according to Dr Steven Wong, a brain cancer expert at Harvard University. Genentech did not want to initiate clinical studies of Avastin in glioblastoma because the neural bleeding risk was so heavily feared, Wong said.
Serious bleeding complications occur in a little less than 5% of the patients who receive Avastin, Wong explained. Also, administering the drug in the time frame of four to six weeks before and after surgery could increase the risk of bleeding in the brain, he added.
A Genentech spokesperson said safety concerns did not emerge in the Phase II study of Avastin in patients with glioblastoma.
However, due to lack of data from randomized controlled clinical studies, physicians estimated that anywhere from 2% to approximately 70% of patients given the drug may experience the side-effect of bleeding. Treatment with Avastin has also caused stroke and hemorrhage in patients with colon and non-small cell lung cancers who have brain metastases, according to oncologists that treat patients with those diseases.
Dr William Leenders, who is currently studying Avastin in this indication, and a physician in the department of pathology at the Raboud University Nijmen Medical Centre, said the likelihood of experiencing a neural hemorrhage after receiving Avastin is approximately 70%. Physicians cannot do anything to minimize patients’ potential risk of bleeding after receiving Avastin and many physicians are wary of administering the drug for glioblastoma due to this risk, Leenders said. Genentech has not seen such a high number of reported adverse events associated with Avastin in a clinical trial for any tumor type, a Genentech spokesperson noted. If this number is based on anecdotal reports from physicians, then it could be very misleading, the spokesperson said. In a Phase II trial for relapsed glioblastoma multiforme, Avastin was well tolerated and associated with low rates of bleeding, she added. Still, Dr Maria Juarez, a specialist at the Cancer Institute of Dallas noted that the rate of neural bleeding in past clinical studies of Avastin was so low, because they excluded patients with brain metastases. Avastin can increase the risk of hemorrhagic stroke, systemic stroke and blood pressure, Juarez said.
Yet Dr Henry Friedman, an investigator who has in the past received research support from Genentech, and who is also the deputy director of the Preston Robert Tisch Brain Tumor Center at Duke University, where Avastin is currently being studied, disagreed and said that the bleeding caused by Avastin is “very rare”. It also does not appear that patients who are on anti-coagulants are at a higher risk for bleeding than those who are not, he added.
The rates of serious bleeding were in the 1-2% range in a clinical study that tested the effects of Avastin and Pfizer’s Campostar (irinotecan) compared to Avastin alone in patients with recurrent glioblastoma multiforme, said Dr Robert Mass, senior group medical director of BioOncology at Genentech. Campostar is a topoisomerase 1 inhibitor that is often administered in combination therapy with Avastin for a variety of indications. This rate of bleeding is acceptable since patients with glioblastoma are prone to experience bleeding as a result of their disease, Mass said.
“We knew that based on the way the drug works, we knew that bleeding is a complication, and there could be an increase in the risk of bleeding,” Mass said.
Patients with colon cancer who have brain metastases are at an increased risk of developing bleeding in the brain when given Avastin, added Dr Alfred Neugut, an oncologist who treats patients with colorectal cancer at Columbia University Medical Center. Physicians are especially concerned that patients given the drug may have a hemorrhagic stroke, Neugut added.
Treatment with Avastin has led to bleeding, and even death as a complication of the hemorrhage according to Dr Rakesh Jain, a brain cancer expert at Harvard University. The side-effects of the drug in this patient population have been published by the Duke University Study Group, Jain said. The drug’s adverse event profile and efficacy needs further study in Phase III clinical trials, he said. Genetech is planning on initiating a Phase III study evaluating Avastin in this patient population, a spokesperson noted. The Phase III trial will evaluate the standard of care of chemotherapy and radiation plus or minus Avastin in newly diagnosed patients with GBM.
Yet due to the lack of available treatments for patients with metastatic glioblastoma, if Avastin is shown to be an efficacious, it would be a major advantage for this patient population, said Dr Chin Wang, an oncologist at the Cancer Institute of Dallas.
Wang agreed that Avastin has been shown to be associated with an increased risk of stroke. It is not known if having glioblastoma and receiving Avastin increases your risk of a stroke even more so than receiving Avastin for other cancer indications, he added.
In addition, patients administered Avastin are at an increased risk for developing an ischemic stroke, which occurs after the formation of a blood clot in a vessel, explained Dr Leia Phioanh Nghiemphu, a specialist studying Avastin at UCLA. Higher rates of ischemic strokes have not occurred in the glioblastoma population to date, Nghiemphu said.
Still, ischemic strokes caused by Avastin could occur at a higher rate in the glioblastoma population which is comprised of older patients, she noted. Older patients receiving Avastin in the colon cancer trials were at an increased risk for developing ischemic strokes, Nghemphu added.
Several cases of cerebral hemorrhage in patients with brain metastases emerged in the studies used to gain FDA approval for Avastin for the non-small cell lung cancer indication. Future studies should investigate if Avastin increases the risk of bleeding in the brain after administering Avastin, Wang said.
The trials used to gain FDA approval for patients with non-small cell lung cancer did not enroll patients with brain metastases, Mass said. Currently Avastin is being studied in clinical trials enrolling patients with non-small cell lung cancer who have brain metastases, he said. The preliminary data that was presented of Avastin in this patient population at ASCO suggests that it is safe to give the drug in this manner, Mass said.
It is important for physicians treating patients with brain metastases to disclose the drug’s potential risk for causing bleeding and stroke, Wang advised. Physicians should also treat patients with chemotherapy or radiotherapy prior to administering Avastin, Wang said. Those treatments would potentially destroy some of the blood vessels feeding the tumor and thereby reduce circulation, Wang added. It is hoped that when the tumor is not actively growing as before, the chance for bleeding and stroke is lower, Wang said.
Nghiemphu, who has studied the drug in small clinical trial enrolling 20 patients, said that Avastin only increases the risk of bleeding by 1-3% in glioblastoma patients. Avastin’s benefits for glioblastoma patients outweigh its risks as glioblastoma is a very deadly cancer with a high risk of recurrence, she said.
Genentech is planning on conducting a randomized clinical trial of Avastin in patients with glioblastoma multiforme, based on the high tumor response rate and tumor free progression that was seen in studies to date, Mass said. “Genentech recognizes the importance of further evaluating Avastin in a randomized Phase III clinical trial in glioblastoma,” the spokesperson said. “The Phase II findings have with Avastin have exceeded our expectations, which is why we plan to submit an sBLA to the FDA for accelerated approval of Avastin,” she added.
Based on data from a Phase II clinical trial that was presented at ASCO this year, 0 out of 84 patients receiving Avastin alone and 3 out of 79 patients receiving Avastin and chemotherapy experienced a grade 3 or higher hemorrhage. A tumor response was seen in 28% of patients treated with Avastin and 38% of patients treated with Avastin in combination with chemotherapy.
Jessme
That's why I think it is the same enzyme. HALO has said repeatedly that they were looking for another supplier and it looks like they found one. Don't know how this bodes for us.
Is this the enzyme we've been producing for HALO?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=31633995
Thanks for that clarification.